Skip to content
value.today
AnaptysBio Inc. logo

AnaptysBio Inc.

Total raised
$49 M
2 rounds on record
Latest round
$41 M
Jul 2015
First round on record
Oct 2011
Today
Went public
See the company page

AnaptysBio Inc. is listed today as AnaptysBio, Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of AnaptysBio Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2015$41 MNo. 2$10 to $50 million

AnaptysBio Inc.: Raise no. 2, Jul 2015

Investors in this round

19 investors had bought by the notice of Jul 24, 2015: 19 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 12 investors are named for AnaptysBio Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$41 M of $41 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Hamza Suria · Executive Officer, Director
  • Marco Londei · Executive Officer
  • Robert Hoffman · Executive Officer
  • Carol Gallagher · Director
  • Hollings Renton · Director
  • James Topper · Director
  • John Schmid · Director
  • Nicholas Lydon · Director
  • Tiba Aynechi · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Hamza Suria, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 24, 2015. Read the notice at the SEC.

equitySEC
Oct 2011$8 MNo. 1$2 to $10 million

AnaptysBio Inc.: Raise no. 1, Oct 2011

Investors in this round

8 investors had bought by the notice of Oct 14, 2011: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 12 investors are named for AnaptysBio Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$8 M of $22 M offered; $14 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Hamza N. Suria · Executive Officer
  • Carol N. Gallagher · Director
  • Heath Lukatch · Director
  • J. Leighton Read · Director
  • James N. Topper · Director
  • Kevin Kinsella · Director
  • Nick Lydon · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total Offering Amount includes Warrants to purchase Preferred Stock exercisable for up to $1,975,606.10. The Warrants have not yet been exercised.”

Signed by Hamza Suria, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 14, 2011. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company AnaptysBio, Inc., its revenue in fiscal 2025 came from these business segments: Royalty Management $234.60 million (100%).

    Annual report (SEC XBRL) · Dec 2025

  • AnaptysBio Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2015).

    SEC Form D · Jul 2015

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jul 2015

Products and services#

No products or services of AnaptysBio Inc. are on record.

Investors#

12 named in official filings. Open an investor to see everything it has backed.

Investors in AnaptysBio Inc.
InvestorKindAmountRoundRoleSource
Carol Giltner GallagherPersonnot statednot statedHeld Series C and D preferred stock, director (Form 3, 2017)SEC Form 3
FHM VII, L.L.C.Othernot statednot statedHeld Series B, C, C-1 and D preferred stock, 10% owner (Form 3, 2017)SEC Form 3
FHM VII, L.P.Fund or asset managernot statednot statedHeld Series B, C, C-1 and D preferred stock, 10% owner (Form 3, 2017)SEC Form 3
FHM V, LLCOthernot statednot statedHeld Series B, C, C-1 and D preferred stock, 10% owner (Form 3, 2017)SEC Form 3
FHM V, LPFund or asset managernot statednot statedHeld Series B, C, C-1 and D preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Frazier Healthcare VII-A, L.P.Fund or asset managernot statednot statedHeld Series B, C, C-1 and D preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Frazier Healthcare VII, L.P.Fund or asset managernot statednot statedHeld Series B, C, C-1 and D preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Frazier Healthcare V, LPFund or asset managernot statednot statedHeld Series B, C, C-1 and D preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Hamza SuriaPersonnot statednot statedHeld Series C, C-1 and D preferred stock, director (Form 3, 2017)SEC Form 3
Marco LondeiPersonnot statednot statedHeld Series D preferred stock (Form 3, 2017)SEC Form 3
Nicholas LydonPersonnot statednot statedHeld Series B, C and D preferred stock, director (Form 3, 2017)SEC Form 3
Novo Holdings A/sFund or asset managernot statednot statedHeld Series B, C, C-1 and D preferred stock, 10% owner (Form 3, 2017)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 19 investors.

Largest shareholders today

Institutions holding AnaptysBio, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by AnaptysBio Inc.
NameRoleNamed in
Hamza SuriaExecutive officerJul 2015
Marco LondeiExecutive officerJul 2015
Robert HoffmanExecutive officerJul 2015
Hamza N. SuriaExecutive officerOct 2011
Carol GallagherDirectorJul 2015
Hamza SuriaDirectorJul 2015
Hollings RentonDirectorJul 2015
James TopperDirectorJul 2015
John SchmidDirectorJul 2015
Nicholas LydonDirectorJul 2015
Tiba AynechiDirectorJul 2015
Carol N. GallagherDirectorOct 2011
Heath LukatchDirectorOct 2011
J. Leighton ReadDirectorOct 2011
James N. TopperDirectorOct 2011
Kevin KinsellaDirectorOct 2011
Nick LydonDirectorOct 2011

Went public since 2017. Its SEC number is that of a company listed on a stock exchange.